Novoron Bioscience

Novoron Bioscience is a biotechnology company based in San Diego, founded in 2014. The company specializes in developing small molecule therapeutics that target lipoprotein receptors, particularly the LDL-receptor family, to address central nervous system disorders. Their focus includes conditions such as neurodegeneration, spinal cord injuries, and related diseases.

The company aims to repair neurological damage and enhance patient independence through innovative therapies. Novoron has received over $3.5 million in NIH grant funding for various projects, including those related to multiple sclerosis, spinal cord injury, stroke, and Alzheimer’s disease. Their current pipeline includes preclinical programs like NOVO-120 for spinal cord injuries and initiatives targeting nephroprotection in kidney diseases. Novoron emphasizes a multi-modality approach to drug discovery and optimized delivery for developing first-in-class treatments.